DOCSLIB.ORG

Japanese Encephalitis Virus and Rabies Vaccines: How Do We Convince Parents to Give Them to Their Traveling Children? John C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Japanese Encephalitis Virus and Rabies Vaccines: How Do We Convince Parents to Give Them to Their Traveling Children? John C Japanese encephalitis virus and rabies vaccines: how do we convince parents to give them to their traveling children? John C. Christenson, MD Ryan White Center for Pediatric Infectious Disease and Global Health Indiana University School of Medicine Riley Hospital for Children CISTM14, Quebec, Canada May 24, 2015 Disclosure information • I have NO financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME activity. • I do intend to discuss unapproved/investigative use of a commercial product/device in my presentation. • I acknowledge that today’s activity is certified for CME credit and thus cannot be promotional. I will give a balanced presentation using the best available evidence to support my conclusions and recommendations. 8/11/2015 3 Why do parents bring their children to travel clinic? • Required vaccine for entry into a country [yellow fever]. • Primary care physician told them to come. • Need for antimalarial prophylaxis. • Want to be completely prepared. • Need for “other” vaccines [hepatitis A, meningococcal, typhoid fever]. • While at visit [“by the way”]: how about rabies vaccine? How about Japanese encephalitis? 8/11/2015 4 Travel vaccines according to risk assessment • Give all available vaccines? • Prioritize recommended vaccines based on: severity, incidence among travelers, expected exposure? Give vaccine if: • High exposure rate [animal bites and rabies], and high mortality if disease develops. • Low exposure rate but with high mortality and sequelae if disease develops [JE]. 8/11/2015 5 Animal bite with rabies risk JEV Rabies Steffen R et al. J Travel Med 2015;22:1-12 8/11/2015 6 Steffen R, Connor BA. J Travel Med 2005;12:26-35 8/11/2015 7 Preventing “rare” infections in travelers: Japanese encephalitis, rabies • “Extremely” low risk of acquiring disease versus serious “untreatable” infections • Evolution of safer vaccines and immune globulins: Biken JE, equine rabies immune globulin • Lack of availability of rabies vaccine and immune globulin for postexposure prophylaxis. • Access to health care facility • Cost 8/11/2015 8 Missionary family to Thailand1 • 5 family members. Children: 7 & 5 years-old, and a 8 month-old. • Planning to stay in country for at least 30 years. Visit others countries in region. • Japanese encephalitis vaccine? • Rabies vaccine? 8/11/2015 9 Traveling to Vietnam to visit family1 • 15 month old boy is traveling with his parents to visit family near Ho Chi Minh City, small farming village near the Mekong River Delta. • Duration of stay: ~3 weeks • Offer Japanese encephalitis vaccine? • Offer rabies vaccines? 8/11/2015 10 Military family traveling to Cambodia for 2 years1 • Father is assigned to Joint POW/MIA Accounting Command. • Mother and 5 children are coming along. They will reside in embassy housing in Phnom Penh. • They anticipate shorts trips [≤7 days] to surrounding countries, including rural areas. • Offer Japanese encephalitis vaccine? • Offer rabies vaccine? 8/11/2015 11 Medical student is a doing an elective in Togo1 • Wants to bring family with him. • Duration of stay: ~2 months. • 11 month-old infant is coming with mother. She is breast feeding. • Rabies vaccine? 8/11/2015 12 High school students traveling in China1 • Visiting Beijing, Hong Kong, Shanghai, and Xian. • Staying in urban areas. • No visits planned to rural areas. • Large group. Traveling on tour buses. • Duration of trip: ~3 weeks • Offer Japanese encephalitis vaccine? • Offer rabies vaccine? 8/11/2015 13 Risk assessment rabies and JE • Rabies: frequent exposures, unknown number of cases prevented by postexposure prophylaxis. • ~1.1 per 100 travelers per month bitten by animals in Southeast Asia. 3.1 per 100 licked. • Japanese encephalitis: one-third of cases occurred in endemic areas with travel <1 month. ~60% in tourists. • Asymptomatic infection common. 1:200 develop clinical disease. 8/11/2015 14 Rabies risk WHO Rabies: the facts • ~100% fatality. • ~50,000-55,000 people die from rabies worldwide each year. • 25,000-30,000 deaths in India alone. • >3 billion people live at risk. • 95% of reported rabies cases: Africa, Asia. • Mostly all bitten by rabid dog. • Preexposure prophylaxis: cost-effective? ~$275,000 per case prevented. • Over 10 years: 22 confirmed rabies in travelers. Africa, Asia, Central America, Haiti, Philippines [6/22 cases]. LeGuerrier P et al. Vaccine 1996;14:167-176. Animal-associated injuries, travelers • GeoSentinel Surveillance Network • 320 cases, 1998-2005 • Median duration of travel: 23 days. • Females > males. More likely to be <15 years. • More animal bites in SE Asia & rest of Asia. • 75% of bites occur in countries endemic for rabies. • Dogs: 51.3% [mostly males]. Monkeys: 21.2% [females] • 66.1% received postexposure prophylaxis. Gautret P et al. Vaccine 2007;25:2656-2663. Rabies postexposure management, travelers, New Zealand • 459 post-travel, 1998-2006: two travel clinics. • 54 exposed to animals abroad. • Mean age: 30.4 years. Highest exposure risk: 16- 30 years of age [38.9%]. 0-15 years [16.7%]. Children 5-15 years: most affected by rabies. • South and SE Asia: 83.3% of exposures. • Most common animal: dogs [66.7%] • 90.7%: no preexposure prophylaxis. Shaw MTM et al. J Travel Med 2009;16:13-17. 8/11/2015 19 Rabies post-exposure [PET], Australia, 2007-20112 780 persons exposed to mammals overseas: • Median age: ~33 years • Age 0-19 years: 32% • 456 [58.5%] received human rabies immune globulin [HRIG]. • 70 [9%] received HRIG abroad. • Mean delay injury-HRIG: 15 days. Kardamanidis K et al. Travel Med Infect Dis 2013;11:421-426. 8/11/2015 20 Rabies: an avoidable infection1 • Avoid exposures • Animal bites: 7th most common health problem, travelers. Children > adults [3-4X]. • Highest risk with longer trips. Median: 5 weeks [Menachem M et al. J Travel Med 2008;6:12-16.] • Dogs bites in 1.3% travelers, average stay, 32 days. • Backpackers, 54% of bites in first 10 days. • Tourists, expatriates, exposure to possible rabid animal: 0.19%-3.2%/year. Warrell MJ. Travel Med Infect Dis 2012;10:1-15. 8/11/2015 21 Rabies: an avoidable infection2 • Young children with lack of inhibitions, inability to protect themselves. • Asia: Playing with, feeding or patting monkeys at the “monkey forest” or “monkey temple”. • Travelers initiated contact with animal: 60% Mills DJ et al. Med J Aust 2011;195:673-675. 8/11/2015 22 Rabies post-exposure [PET], Australia, 2007-20111 • Free rabies post-exposure treatment, New South Wales. • 1195 people received PET. 780 exposed abroad. 78.3% in SE Asia. 47.6% in Indonesia [Bali: 95.2%]. • Injuries abroad: 49.4% monkey bites, dogs 35.8%. • Vaccination, pre-exposure, international traveler: 4% Kardamanidis K et al. Travel Med Infect Dis 8/11/2015 2013;11:421-426. 23 Does your child need rabies vaccine? • Risk assessment: infant vs toddler vs adolescent • Recreational or occupational activities: example; mission work with vet vaccinating farm animals and pets • Length of stay in country • Nearest health care facility • Availability of rabies immunoglobulin and vaccines in-country • Financial Global availability of rabies immune globulin: direct care providers to travelers Jentes ES et al. J Travel Med 2013;20:148-158. 8/11/2015 25 Global availability of rabies vaccine: direct care providers to travelers Jentes ES et al. J Travel Med 2013;20:148-158. 8/11/2015 26 Global availability of rabies immune globulin: direct care providers to travelers1 • Global survey to travel medicine providers and clinics, 2011. Never or Often or Region Sometimes seldom always Australia & 6% 0 94% Pacific Islands North America 19% 7% 74% Tropical South 80% 0 20% America South Asia 0 11% 89% Jentes ES et al. J Travel Med 2013;20:148-158. 8/11/2015 27 Global availability of rabies immune globulin: direct care providers to travelers2 Never or Often or Region Sometimes seldom always Western Europe 22% 0 78% Mexico, Central America & 100% 0 0 Caribbean East & SE Asia 33% 0 67% West, Central & East Africa 25% 25% 50% Jentes ES et al. J Travel Med 2013;20:148-158. 8/11/2015 28 Type of rabies immune globulin: direct care providers to travelers3 Region HRIG ERIG Unknown Western Europe 77% 0 13% Mexico, Central 100% 0 0 America & Caribbean East & SE Asia 60% 20% 0 West, Central & East 33% 33% 0 Africa South Africa 82% 0 18% Jentes ES et al. J Travel Med 2013;20:148-158. 8/11/2015 29 Global availability of rabies IG and vaccine: US embassies survey Rabies immune globulin available: Never or Often or Sometimes seldom always 0-50% [12] 0-58% [25] 8-100% [63] Rabies vaccine available: Never or Often or Sometimes seldom always 0-33% [10] 0-47% [21] 42-100% [69] Jentes ES et al. J Travel Med 2013;20:148-158. 8/11/2015 30 Rabies: CDC Public Image Library 8/11/2015 31 JEV epidemiology • The main JEV transmission cycle involves Culex tritaeniorhynchus mosquitoes. • <1% of human JEV infections result in encephalitis. Humans are dead-end hosts. • JE is primarily a disease of children. Most adults have natural immunity after childhood infection. • Most temperate areas, Asia, transmission mainly during the warm season [May-October]. • Tropics and subtropics: transmission occurs year-round. Intensifies during rainy season. Shlim DR, Solomon T. Clin Infect Dis 2002;35:183-188. 8/11/2015 32 Japanese encephalitis: epidemiology, risk in travelers1 • Japanese encephalitis virus (JEV): mosquito- borne flavivirus. • Important cause of severe encephalitis in Asia. • Case fatality rate: 20-30%. • Neurologic or psychiatric sequelae, survivors: 30-50%. • No antiviral therapy is available. Disease is vaccine-preventable. Campbell GL et al. Bull World Health Organ 2011;89:766-774. CDC Public Image Library: Western Cambodia’s, Battambang province, 2013 8/11/2015 34 Deshpande BR et al.
Load more

Recommended publications
  • Zika Virus Outside Africa Edward B
    Zika Virus Outside Africa Edward B. Hayes Zika virus (ZIKV) is a flavivirus related to yellow fever, est (4). Serologic studies indicated that humans could also dengue, West Nile, and Japanese encephalitis viruses. In be infected (5). Transmission of ZIKV by artificially fed 2007 ZIKV caused an outbreak of relatively mild disease Ae. aegypti mosquitoes to mice and a monkey in a labora- characterized by rash, arthralgia, and conjunctivitis on Yap tory was reported in 1956 (6). Island in the southwestern Pacific Ocean. This was the first ZIKV was isolated from humans in Nigeria during time that ZIKV was detected outside of Africa and Asia. The studies conducted in 1968 and during 1971–1975; in 1 history, transmission dynamics, virology, and clinical mani- festations of ZIKV disease are discussed, along with the study, 40% of the persons tested had neutralizing antibody possibility for diagnostic confusion between ZIKV illness to ZIKV (7–9). Human isolates were obtained from febrile and dengue. The emergence of ZIKV outside of its previ- children 10 months, 2 years (2 cases), and 3 years of age, ously known geographic range should prompt awareness of all without other clinical details described, and from a 10 the potential for ZIKV to spread to other Pacific islands and year-old boy with fever, headache, and body pains (7,8). the Americas. From 1951 through 1981, serologic evidence of human ZIKV infection was reported from other African coun- tries such as Uganda, Tanzania, Egypt, Central African n April 2007, an outbreak of illness characterized by rash, Republic, Sierra Leone (10), and Gabon, and in parts of arthralgia, and conjunctivitis was reported on Yap Island I Asia including India, Malaysia, the Philippines, Thailand, in the Federated States of Micronesia.
    [Show full text]
  • Japanese Encephalitis
    J Neurol Neurosurg Psychiatry 2000;68:405–415 405 NEUROLOGICAL ASPECTS OF TROPICAL DISEASE Japanese encephalitis Tom Solomon, Nguyen Minh Dung, Rachel Kneen, Mary Gainsborough, David W Vaughn, Vo Thi Khanh Although considered by many in the west to be West Nile virus, a flavivirus found in Africa, the a rare and exotic infection, Japanese encephali- Middle East, and parts of Europe, is tradition- tis is numerically one of the most important ally associated with a syndrome of fever causes of viral encephalitis worldwide, with an arthralgia and rash, and with occasional estimated 50 000 cases and 15 000 deaths nervous system disease. However, in 1996 West annually.12About one third of patients die, and Nile virus caused an outbreak of encephalitis in half of the survivors have severe neuropshychi- Romania,5 and a West Nile-like flavivirus was atric sequelae. Most of China, Southeast Asia, responsible for an encephalitis outbreak in and the Indian subcontinent are aVected by the New York in 1999.67 virus, which is spreading at an alarming rate. In In northern Europe and northern Asia, flavi- these areas, wards full of children and young viruses have evolved to use ticks as vectors adults aZicted by Japanese encephalitis attest because they are more abundant than mosqui- Department of to its importance. toes in cooler climates. Far eastern tick-borne Neurological Science, University of encephalitis virus (also known as Russian Liverpool, Walton Historical perspective spring-summer encephalitis virus) is endemic Centre for Neurology Epidemics of encephalitis were described in in the eastern part of the former USSR, and and Neurosurgery, Japan from the 1870s onwards.
    [Show full text]
  • A Replication-Defective Japanese Encephalitis Virus (JEV)
    www.nature.com/npjvaccines ARTICLE OPEN A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice ✉ Na Li1,2, Zhe-Rui Zhang1,2, Ya-Nan Zhang1,2, Jing Liu1,2, Cheng-Lin Deng1, Pei-Yong Shi3, Zhi-Ming Yuan1, Han-Qing Ye 1 and ✉ Bo Zhang 1,4 In our previous study, we have demonstrated in the context of WNV-ΔNS1 vaccine (a replication-defective West Nile virus (WNV) lacking NS1) that the NS1 trans-complementation system may offer a promising platform for the development of safe and efficient flavivirus vaccines only requiring one dose. Here, we produced high titer (107 IU/ml) replication-defective Japanese encephalitis virus (JEV) with NS1 deletion (JEV-ΔNS1) in the BHK-21 cell line stably expressing NS1 (BHKNS1) using the same strategy. JEV-ΔNS1 appeared safe with a remarkable genetic stability and high degrees of attenuation of in vivo neuroinvasiveness and neurovirulence. Meanwhile, it was demonstrated to be highly immunogenic in mice after a single dose, providing similar degrees of protection to SA14-14-2 vaccine (a most widely used live attenuated JEV vaccine), with healthy condition, undetectable viremia and gradually rising body weight. Importantly, we also found JEV-ΔNS1 induced robust cross-protective immune responses against the challenge of heterologous West Nile virus (WNV), another important member in the same JEV serocomplex, accounting for up to 80% survival rate following a single dose of immunization relative to mock-vaccinated mice. These results not only support the identification of 1234567890():,; the NS1-deleted flavivirus vaccines with a satisfied balance between safety and efficacy, but also demonstrate the potential of the JEV-ΔNS1 as an alternative vaccine candidate against both JEV and WNV challenge.
    [Show full text]
  • Clinically Important Vector-Borne Diseases of Europe
    Natalie Cleton, DVM Erasmus MC, Rotterdam Department of Viroscience [email protected] No potential conflicts of interest to disclose © by author ESCMID Online Lecture Library Erasmus Medical Centre Department of Viroscience Laboratory Diagnosis of Arboviruses © by author Natalie Cleton ESCMID Online LectureMarion Library Koopmans Chantal Reusken [email protected] Distribution Arboviruses with public health impact have a global and ever changing distribution © by author ESCMID Online Lecture Library Notifications of vector-borne diseases in the last 6 months on Healthmap.org Syndromes of arboviral diseases 1) Febrile syndrome: – Fever & Malaise – Headache & retro-orbital pain – Myalgia 2) Neurological syndrome: – Meningitis, encephalitis & myelitis – Convulsions & coma – Paralysis 3) Hemorrhagic syndrome: – Low platelet count, liver enlargement – Petechiae © by author – Spontaneous or persistent bleeding – Shock 4) Arthralgia,ESCMID Arthritis and Online Rash: Lecture Library – Exanthema or maculopapular rash – Polyarthralgia & polyarthritis Human arboviruses: 4 main virus families Family Genus Species examples Flaviviridae flavivirus Dengue 1-5 (DENV) West Nile virus (WNV) Yellow fever virus (YFV) Zika virus (ZIKV) Tick-borne encephalitis virus (TBEV) Togaviridae alphavirus Chikungunya virus (CHIKV) O’Nyong Nyong virus (ONNV) Mayaro virus (MAYV) Sindbis virus (SINV) Ross River virus (RRV) Barmah forest virus (BFV) Bunyaviridae nairo-, phlebo-©, orthobunyavirus by authorCrimean -Congo heamoragic fever (CCHFV) Sandfly fever virus
    [Show full text]
  • Virulence of Japanese Encephalitis Virus Genotypes I and III, Taiwan
    Virulence of Japanese Encephalitis Virus Genotypes I and III, Taiwan Yi-Chin Fan,1 Jen-Wei Lin,1 Shu-Ying Liao, within a year (8,9), which provided an excellent opportu- Jo-Mei Chen, Yi-Ying Chen, Hsien-Chung Chiu, nity to study the transmission dynamics and pathogenicity Chen-Chang Shih, Chi-Ming Chen, of these 2 JEV genotypes. Ruey-Yi Chang, Chwan-Chuen King, A mouse model showed that the pathogenic potential Wei-June Chen, Yi-Ting Ko, Chao-Chin Chang, is similar among different JEV genotypes (10). However, Shyan-Song Chiou the pathogenic difference between GI and GIII virus infec- tions among humans remains unclear. Endy et al. report- The virulence of genotype I (GI) Japanese encephalitis vi- ed that the proportion of asymptomatic infected persons rus (JEV) is under debate. We investigated differences in among total infected persons (asymptomatic ratio) is an the virulence of GI and GIII JEV by calculating asymptomat- excellent indicator for estimating virulence or pathogenic- ic ratios based on serologic studies during GI- and GIII-JEV endemic periods. The results suggested equal virulence of ity of dengue virus infections among humans (11). We used GI and GIII JEV among humans. the asymptomatic ratio method for a study to determine if GI JEV is associated with lower virulence than GIII JEV among humans in Taiwan. apanese encephalitis virus (JEV), a mosquitoborne Jflavivirus, causes Japanese encephalitis (JE). This virus The Study has been reported in Southeast Asia and Western Pacific re- JEVs were identified in 6 locations in Taiwan during 1994– gions since it emerged during the 1870s in Japan (1).
    [Show full text]
  • Hantavirus Infection Is Inhibited by Griffithsin in Cell Culture
    BRIEF RESEARCH REPORT published: 04 November 2020 doi: 10.3389/fcimb.2020.561502 Hantavirus Infection Is Inhibited by Griffithsin in Cell Culture Punya Shrivastava-Ranjan 1, Michael K. Lo 1, Payel Chatterjee 1, Mike Flint 1, Stuart T. Nichol 1, Joel M. Montgomery 1, Barry R. O’Keefe 2,3 and Christina F. Spiropoulou 1* 1 Division of High Consequence Pathogens and Pathology, Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States, 2 Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States, 3 Division of Cancer Treatment and Diagnosis, Natural Products Branch, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD, United States Andes virus (ANDV) and Sin Nombre virus (SNV), highly pathogenic hantaviruses, cause hantavirus pulmonary syndrome in the Americas. Currently no therapeutics are approved for use against these infections. Griffithsin (GRFT) is a high-mannose oligosaccharide-binding lectin currently being evaluated in phase I clinical trials as a topical microbicide for the prevention of human immunodeficiency virus (HIV-1) infection (ClinicalTrials.gov Identifiers: NCT04032717, NCT02875119) and has shown Edited by: broad-spectrum in vivo activity against other viruses, including severe acute respiratory Alemka Markotic, syndrome coronavirus, hepatitis C virus, Japanese encephalitis virus, and Nipah virus. University Hospital for Infectious Diseases “Dr. Fran Mihaljevic,” Croatia In this study, we evaluated the in vitro antiviral activity of GRFT and its synthetic trimeric Reviewed by: tandemer 3mGRFT against ANDV and SNV. Our results demonstrate that GRFT is a Zhilong Yang, potent inhibitor of ANDV infection. GRFT inhibited entry of pseudo-particles typed with Kansas State University, United States ANDV envelope glycoprotein into host cells, suggesting that it inhibits viral envelope Gill Diamond, University of Louisville, United States protein function during entry.
    [Show full text]
  • Inactivated Japanese Encephalitis Virus Vaccine
    January 8, 1993 / Vol. 42 / No. RR-1 CENTERS FOR DISEASE CONTROL AND PREVENTION Recommendations and Reports Inactivated Japanese Encephalitis Virus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP) U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention (CDC) Atlanta, Georgia 30333 The MMWR series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), Public Health Service, U.S. Depart- ment of Health and Human Services, Atlanta, Georgia 30333. SUGGESTED CITATION Centers for Disease Control and Prevention. Inactivated Japanese encephalitis vi- rus vaccine. Recommendations of the advisory committee on immunization practices (ACIP). MMWR 1993;42(No. RR-1):[inclusive page numbers]. Centers for Disease Control and Prevention .................... William L. Roper, M.D., M.P.H. Director The material in this report was prepared for publication by: National Center for Infectious Diseases..................................James M. Hughes, M.D. Director Division of Vector-Borne Infectious Diseases ........................Duane J. Gubler, Sc.D. Director The production of this report as an MMWR serial publication was coordinated in: Epidemiology Program Office.................................... Stephen B. Thacker, M.D., M.Sc. Director Richard A. Goodman, M.D., M.P.H. Editor, MMWR Series Scientific Information and Communications Program Recommendations and Reports ................................... Suzanne M. Hewitt, M.P.A. Managing Editor Sharon D. Hoskins Project Editor Rachel J. Wilson Editorial Trainee Peter M. Jenkins Visual Information Specialist Use of trade names is for identification only and does not imply endorsement by the Public Health Service or the U.S. Department of Health and Human Services.
    [Show full text]
  • Competency of Amphibians and Reptiles and Their Potential Role As Reservoir Hosts for Rift Valley Fever Virus
    viruses Article Competency of Amphibians and Reptiles and Their Potential Role as Reservoir Hosts for Rift Valley Fever Virus Melanie Rissmann 1, Nils Kley 1, Reiner Ulrich 2,3 , Franziska Stoek 1, Anne Balkema-Buschmann 1 , Martin Eiden 1 and Martin H. Groschup 1,* 1 Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany; melanie.rissmann@fli.de (M.R.); [email protected] (N.K.); franziska.stoek@fli.de (F.S.); anne.balkema-buschmann@fli.de (A.B.-B.); martin.eiden@fli.de (M.E.) 2 Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany; [email protected] 3 Institute of Veterinary Pathology, Leipzig University, 04103 Leipzig, Germany * Correspondence: martin.groschup@fli.de; Tel.: +49-38351-7-1163 Received: 10 September 2020; Accepted: 19 October 2020; Published: 23 October 2020 Abstract: Rift Valley fever phlebovirus (RVFV) is an arthropod-borne zoonotic pathogen, which is endemic in Africa, causing large epidemics, characterized by severe diseases in ruminants but also in humans. As in vitro and field investigations proposed amphibians and reptiles to potentially play a role in the enzootic amplification of the virus, we experimentally infected African common toads and common agamas with two RVFV strains. Lymph or sera, as well as oral, cutaneous and anal swabs were collected from the challenged animals to investigate seroconversion, viremia and virus shedding. Furthermore, groups of animals were euthanized 3, 10 and 21 days post-infection (dpi) to examine viral loads in different tissues during the infection. Our data show for the first time that toads are refractory to RVFV infection, showing neither seroconversion, viremia, shedding nor tissue manifestation.
    [Show full text]
  • Preparedness and Response for Chikungunya Virus: Introduction in the Americas Washington, D.C.: PAHO, © 2011
    O P S N N O PR O V United States of America Washington, D.C. 20037, 525 Twenty-third Street, N.W., I S M A U L U N T D E I O H P A PAHO/CDC PREparEDNESS AND RESPONSE FOR CHIKUNGUNYA VIRUS INTRODUCTION IN THE AMERICAS Chikungunya Virus Chikungunya Introduction in theAmericas in Introduction Preparedness andResponse for Preparedness and Response for Chikungunya Virus Introduction in the Americas S A LU O T R E P O P A P H S O N I O D V I M U N PAHO HQ Library Cataloguing-in-Publication Pan American Health Organization Preparedness and Response for Chikungunya Virus: Introduction in the Americas Washington, D.C.: PAHO, © 2011 ISBN: 978-92-75-11632-6 I. Title 1. VECTOR CONTROL 2. COMMUNICABLE DISEASE CONTROL 3. EPIDEMIOLOGIC SURVEILLANCE 4. DISEASE OUTBREAKS 5. VIRUS DISEASE - transmission 6. LABORATORY TECHNIQUES AND PROCEDURES 7. AMERICAS NLM QX 650.DA1 The Pan American Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and inquiries should be addressed to Editorial Services, Area of Knowledge Management and Communications (KMC), Pan American Health Organization, Washington, D.C., U.S.A. The Area for Health Surveillance and Disease Prevention and Control, Project for Alert and Response and Epidemic Diseases, at (202) 974-3010 or via email at [email protected], will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available. ©Pan American Health Organization, 2011.
    [Show full text]
  • Speaker Notes
    Japanese Encephalitis S Japanese encephalitis is a mosquito-borne viral infection of horses, pigs l and humans. It is also referred to as Japanese B encephalitis, arbovirus B, i and mosquito-borne encephalitis virus. d Japanese Encephalitis e Japanese B Encephalitis, Arbovirus B 1 S In today’s presentation we will cover information regarding the organism l Overview that causes Japanese encephalitis and the epidemiology of the disease. We i • Economic Impact will also talk about the economic impact the disease has had in the past • Epidemiology and could have in the future. Additionally, we will talk about how it is d • Transmission transmitted, the species it affects, the clinical signs and necropsy findings, e • Clinical Signs as well as the diagnosis and treatment of the disease. Finally, we will • Diagnosis and Treatment • Disease in Humans address prevention and control measures for the disease as well as actions 2 • Prevention and Control to take if Japanese encephalitis is suspected. • Actions to Take Center for Food Security and Public Health, Iowa State University, 2011 (Photo of Culex mosquito laying eggs, from CDC website at www.cdc.gov/ncidod/dvbid/jencphalitis) S l i d The Organism e 3 S Japanese Encephalitis (JE) virus belongs to the genus Flavivirus in the l Japanese Encephalitis family Flaviviridae (related to St. Louis encephalitis virus, Murray valley i • Genus Flavivirus virus, and West Nile virus). The name of the family is derived from the • Name derived from Latin ‘flavus’ meaning yellow, which refers to the yellow fever virus, d the Latin flavus meaning also a member of this family.
    [Show full text]
  • Japanese Encephalitis
    Alberta Health Public Health Disease Management Guidelines Japanese Encephalitis Revision Dates Case Definition March 2011 Reporting Requirements May 2018 Remainder of the Guideline (i.e., Etiology to References sections inclusive) March 2011 Case Definition Confirmed Case Clinical illness(A) with laboratory confirmation of infection: Isolation of japanese encephalitis virus (JE) from an appropriate clinical specimen OR Detection of JE viral nucleic acid (e.g., PCR) in an appropriate clinical specimen OR Seroconversion or significant difference between acute and convalescent phase JE HAI titres ideally taken at least 2 weeks apart and confirmed by PRNT(B,C). Probable Case Clinical illness(A) and one of the following: Seroconversion or significant difference between acute and convalescent phase JE HAI titres ideally taken at least 2 weeks apart but not confirmed by PRNT(B) OR Stable elevated serial HAI titres(D) to JE that occur during a period when and where arboviral transmission is likely(E) OR Single elevated HAI titre(D) to JE that occurs during a period when and where arboviral transmission is likely(E). (A) Clinical illness is characterized by a febrile illness of variable severity associated with neurological symptoms ranging from headache to aseptic meningitis or encephalitis. Arboviral encephalitis cannot be distinguished clinically from other central nervous system (CNS) infections. Symptoms can include headache, confusion or other alteration in sensorium, nausea and vomiting. Signs may include fever, meningismus, cranial nerve palsies, paresis or paralysis, sensory deficits, altered reflexes, convulsions, abnormal movements and coma of varying degree. (B) Seroconversion indicates recent infection with a flavivirus (e.g., dengue fever, California serogroup, West Nile virus or yellow fever) but cannot pinpoint which one due to antibody cross-reactivity.
    [Show full text]
  • Japanese Encephalitis Virus Complex Mediated Amplification Assay (Procleix, Novartis)
    Japanese Encephalitis Virus Complex mediated amplification assay (Procleix, Novartis). The same patient was negative when tested with the Cobas Taqscreen Disease Agent: (Roche) WNV PCR assay. • Japanese encephalitis virus (JEV) and Usutu virus Common Human Exposure Routes: (USUV) • Vector-borne (Culex mosquitoes) Disease Agent Characteristics: Likelihood of Secondary Transmission: • Family: Flaviviridae; Genus: Flavivirus • Virion morphology and size: Enveloped, icosahedral nucleo- • For JEV, absent except for rare intrauterine transmission capsid symmetry, spherical particles, 40 to 60 nm in recorded diameter • Undocumented for USUV • Nucleic acid: Linear, positive-sense, single-stranded RNA At-Risk Populations: genome, ~11.0 kb in length • Physicochemical properties: Infectivity inactivated and • Widely distributed in Asia destroyed by heating for 10 minutes at >56°C; half life of 7 • Affects all ages, but especially children and the elderly hours at 37°C; sensitive to treatment with lipid solvents, Vector and Reservoir Involved: detergents, ether, trypsin, chloroform, formaldehyde, heat and b-propiolactone; infectivity reduced after exposure to • Main epidemic JEV vectors are mosquitoes of the Culex irradiation and inactivated at pH 1-3 species, especially C. tritaeniorhynchus, which is an evening- and nighttime-biting mosquito that feeds preferentially on Disease Name: pigs and birds and infrequently on humans. Culicine mos- • Japanese encephalitis quitos are also the vectors for USUV. • In temperate regions, pigs and birds (principally ardeid Priority Level: species, such as egrets and black-crowned night herons, and • Scientific/Epidemiologic evidence regarding blood safety: possibly ducks) are effective amplifying hosts for JEV. USUV Theoretical; because of the similarity to West Nile virus circulates in birds. (WNV), transfusion risk during JEV outbreaks may occur.
    [Show full text]